30
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Background and Aims:

          NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach.

          Approach and Results:

          PubMed and Ovid MEDLINE were searched for NAFLD population-based studies from 1990 to 2019 survey year (last published 2022) per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Meta-analysis was conducted using random-effects models. Bias risk assessment was per Joanna Briggs Institute. Of 2585 studies reviewed, 92 studies (N=9,361,716) met eligibility criteria. Across the study period (1990–2019), meta-analytic pooling of NAFLD prevalence estimates and ultrasound-defined NAFLD yielded an overall global prevalence of 30.05% (95% CI: 27.88%–32.32%) and 30.69% (28.4–33.09), respectively. Global NAFLD prevalence increased by +50.4% from 25.26% (21.59–29.33) in 1990–2006 to 38.00% (33.71–42.49) in 2016–2019 ( p<0.001); ultrasound-defined NAFLD prevalence increased by +38.7% from 25.16% (19.46–31.87) in 1990–2006 to 34.59% (29.05–40.57) ( p=0.029). The highest NAFLD prevalence was in Latin America 44.37% (30.66%–59.00%), then Middle East and North Africa (MENA) (36.53%, 28.63%–45.22%), South Asia (33.83%, 22.91%–46.79%), South-East Asia (33.07%, 18.99%–51.03%), North America (31.20%, 25.86%–37.08%), East Asia (29.71%, 25.96%–33.76%), Asia Pacific 28.02% (24.69%–31.60%), Western Europe 25.10% (20.55%–30.28%). Among the NAFLD cohort diagnosed without a liver biopsy, pooled mortality rate per 1000 PY was 12.60 (6.68–23.67) for all-cause mortality; 4.20 (1.34–7.05) for cardiac-specific mortality; 2.83 (0.78–4.88) for extrahepatic cancer-specific mortality; and 0.92 (0.00–2.21) for liver-specific mortality.

          Conclusions:

          NAFLD global prevalence is 30% and increasing which requires urgent and comprehensive strategies to raise awareness and address all aspects of NAFLD on local, regional, and global levels.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: not found
          • Article: not found

          Bias in meta-analysis detected by a simple, graphical test

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Meta-analysis in clinical trials

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Conducting Meta-Analyses inRwith themetaforPackage

                Bookmark

                Author and article information

                Contributors
                Journal
                Hepatology
                Hepatology
                HEP
                Hepatology (Baltimore, Md.)
                Lippincott Williams & Wilkins (Hagerstown, MD )
                0270-9139
                1527-3350
                April 2023
                03 January 2023
                : 77
                : 4
                : 1335-1347
                Affiliations
                [1 ]Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA
                [2 ]Department of Medicine, Center for Liver Disease, Inova Fairfax Medical Campus, Falls Church, Virginia, USA
                [3 ]Inova Medicine, Inova Health System, Falls Church, Virginia, USA
                Author notes
                Correspondence Zobair M. Younossi, Inova Medicine, Inova Health System, Department of Medicine, Inova Fairfax Medical Campus, Betty and Guy Beatty Center for Integrated Research, Claude Moore Health Education and Research Building, 3300 Gallows Road, Falls Church, VA 22042. Email: zobair.younossi@ 123456inova.org
                Article
                00027
                10.1097/HEP.0000000000000004
                10026948
                36626630
                07fa02d2-feb0-4ee8-93de-4b3d5c9acc35
                Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of American Association for the Study of Liver Diseases.

                This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/

                History
                : 10 July 2022
                : 28 September 2022
                : 30 September 2022
                Categories
                Original Articles: Steatohepatitis
                Custom metadata
                T
                TRUE

                Gastroenterology & Hepatology
                Gastroenterology & Hepatology

                Comments

                Comment on this article